My NCBI | Sign In
RSS Settings
  • Search: van der Steeg WA[au]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 13

    1.

    Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.

    Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, Deedwania P, Olsson AG, Boekholdt SM, Demicco DA, Szarek M, LaRosa JC, Pedersen TR, Grundy SM; TNT Study Group; IDEAL Study Group.

    Circulation. 2008 Jun 10;117(23):3002-9. Epub 2008 Jun 2.PMID: 18519851 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrometry.

    ter Heine R, Rosing H, van Gorp EC, Mulder JW, van der Steeg WA, Beijnen JH, Huitema AD.

    J Chromatogr B Analyt Technol Biomed Life Sci. 2008 May 15;867(2):205-12. Epub 2008 Apr 8.PMID: 18456582 [PubMed - indexed for MEDLINE]Related articles

    3.

    High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies.

    van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, Tikkanen MJ, Wareham NJ, Faergeman O, Olsson AG, Pedersen TR, Khaw KT, Kastelein JJ.

    J Am Coll Cardiol. 2008 Feb 12;51(6):634-42.PMID: 18261682 [PubMed - indexed for MEDLINE]Related articles

    4.

    ApoB/A1 and LDL-C/HDL-C and the prediction of cardiovascular risk in statin-treated patients.

    Liem AH, van de Woestijne AP, Roeters van Lennep HW, Zwinderman AH, van der Steeg WA, Jukema JW.

    Curr Med Res Opin. 2008 Feb;24(2):359-64.PMID: 18081989 [PubMed - indexed for MEDLINE]Related articles

    5.

    The role of CETP inhibition in dyslipidemia.

    El Harchaoui K, van der Steeg WA, Stroes ES, Kastelein JJ.

    Curr Atheroscler Rep. 2007 Aug;9(2):125-33. Review.PMID: 17877921 [PubMed - indexed for MEDLINE]Related articles

    6.

    Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk.

    van der Steeg WA, Boekholdt SM, Stein EA, El-Harchaoui K, Stroes ES, Sandhu MS, Wareham NJ, Jukema JW, Luben R, Zwinderman AH, Kastelein JJ, Khaw KT.

    Ann Intern Med. 2007 May 1;146(9):640-8.PMID: 17470832 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin.

    Ozsoy RC, van der Steeg WA, Kastelein JJ, Arisz L, Koopman MG.

    Nephrol Dial Transplant. 2007 Jun;22(6):1578-86. Epub 2007 Mar 8.PMID: 17347284 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study.

    El Harchaoui K, van der Steeg WA, Stroes ES, Kuivenhoven JA, Otvos JD, Wareham NJ, Hutten BA, Kastelein JJ, Khaw KT, Boekholdt SM.

    J Am Coll Cardiol. 2007 Feb 6;49(5):547-53. Epub 2007 Jan 22.PMID: 17276177 [PubMed - indexed for MEDLINE]Related articles

    9.

    Cholesteryl ester transfer protein and hyperalphalipoproteinemia in Caucasians.

    van der Steeg WA, Hovingh GK, Klerkx AH, Hutten BA, Nootenboom IC, Levels JH, van Tol A, Dallinga-Thie GM, Zwinderman AH, Kastelein JJ, Kuivenhoven JA.

    J Lipid Res. 2007 Mar;48(3):674-82. Epub 2006 Dec 27.PMID: 17192423 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    [The role of the high-density lipoprotein (HDL) particle in atherogenesis and potential methods to increase HDL concentrations]

    Birjmohun RS, van der Steeg WA, Stroes ES, Kastelein JJ.

    Ned Tijdschr Geneeskd. 2006 Oct 14;150(41):2245-50. Review. Dutch. PMID: 17076358 [PubMed - indexed for MEDLINE]Related articles

    11.

    Increasing high-density lipoprotein cholesterol through cholesteryl Ester transfer protein inhibition: a next step in the fight against cardiovascular disease?

    Van der Steeg WA, El-Harchaoui K, Kuivenhoven JA, Kastelein JJ.

    Curr Drug Targets Cardiovasc Haematol Disord. 2005 Dec;5(6):481-8. Review.PMID: 16503868 [PubMed - indexed for MEDLINE]Related articles

    12.

    Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.

    Klerkx AH, El Harchaoui K, van der Steeg WA, Boekholdt SM, Stroes ES, Kastelein JJ, Kuivenhoven JA.

    Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):706-15. Epub 2006 Jan 26. Review.PMID: 16439711 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Role of CETP inhibitors in the treatment of dyslipidemia.

    van der Steeg WA, Kuivenhoven JA, Klerkx AH, Boekholdt SM, Hovingh GK, Kastelein JJ.

    Curr Opin Lipidol. 2004 Dec;15(6):631-6. Review.PMID: 15529021 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Search details

    » See more...

    Recent activity